Michael R. Hayden - 24 Aug 2026 Form 4 Insider Report for AbCellera Biologics Inc. (ABCL)

Reporting relationship: Director
Issuer ticker: ABCL
Reported as of: 24 Aug 2026
Net transaction value: +$570,442
SEC form: 4
Accepted by SEC: 24 Aug 2026, 17:21:48 UTC
Prior SEC filing: 14 Aug 2026
Source filing: View source filing
Reporting owner signature: Tryn Stimart, attorney-in-fact

Key filing fact

Michael R. Hayden filed Form 4 for AbCellera Biologics Inc. (ABCL) on 24 Aug 2026.

Key facts

This page summarizes Michael R. Hayden's Form 4 filing for AbCellera Biologics Inc. (ABCL).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 24 Aug 2026, 17:21.

Change

Previous filing in this sequence was filed on 14 Aug 2026.
Current net transaction value: +$570,442.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001352908 Primary reporting owner

Hayden Michael R

Relationship: Director
Address: C/O ABCELLERA BIOLOGICS INC, 150 W 4TH AVENUE, VANCOUVER, BRITISH COLUMBIA, CANADA
Signature: Tryn Stimart, attorney-in-fact
Signature date: 24 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ABCL transaction

Common Shares

Purchase

Transaction value: $570,442
Shares: +53,613
Change %: +4.1%
Price: $10.64
Shares after: 1,373,397
Date: 24 Aug 2026
Ownership: See footnote
Footnotes: F1, F2

ABCL holding

Common Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 118,245
Date: 24 Aug 2026
Ownership: By spouse

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The price reported in Column 4 is a weighted-average price. These shares were acquired in multiple transactions at prices ranging from $10.49 to $10.70. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.

Footnote F2

These shares are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein.